BridgeMD
Tests treatment safety and results for Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
Official title Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
ClinicalTrials.gov ID: NCT06909877
What this study is testing
What is HH2853 Tablets?
HH2853 Tablets is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for relapsed/refractory peripheral t-cell lymphoma (r/r ptcl).
Also referred to as HH2853.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is a an open-label, multinational, multicenter, single-arm Phase Ⅰb/Ⅱ Study to Evaluate Efficacy and Safety of Oral HH2853 in Patients with Relapsed/Refractory Peripheral T-cell Lymphoma.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- main inclusion:
- Tumor types and prior antitumor therapy: Phase Ib:Dose Escalation: All enrolled patients must have histologically confirmed diagnosis NHL who have...
- Availability of qualified tissue samples by patient for pathological diagnosis by the central laboratory.
- The Eastern cooperative oncology group (ECOG) score 0-1.
- Life expectancy ≥ 3 months before starting HH2853 treatment.
You likely can't join if
- main criteria:
- Previous treatment with EZH2 or EZH1/2 inhibitors.
- Central nervous system invasion.
- Any previous history of bone marrow malignancy, including myelodysplastic syndrome (MDS).
- Received medications that are known potent CYP3A4 inducers/inhibitors within 1 week prior to first dose.
See the full eligibility criteria
- main inclusion:
- Tumor types and prior antitumor therapy: Phase Ib:Dose Escalation: All enrolled patients must have histologically confirmed diagnosis NHL who have received at least one line of prior systematic treatment (and ≤ 5 lines)...
- Availability of qualified tissue samples by patient for pathological diagnosis by the central laboratory.
- The Eastern cooperative oncology group (ECOG) score 0-1.
- Life expectancy ≥ 3 months before starting HH2853 treatment.
- Sufficient bone marrow, liver and renal functions.
- main criteria:
- Previous treatment with EZH2 or EZH1/2 inhibitors.
- Central nervous system invasion.
- Any previous history of bone marrow malignancy, including myelodysplastic syndrome (MDS).
- Received medications that are known potent CYP3A4 inducers/inhibitors within 1 week prior to first dose.
The study team makes the final eligibility decision.
Where it's taking place
- Chengdu, Chengdu, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Chengdu, Chengdu, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.